buntanetap — Clinical data readout
H2 2026
We expect the 6-month symptomatic component of the combined AD trial to read-out in the second half of 2026.Source filing
ANVS biotech catalysts & pipeline
ANNOVIS BIO INC · Data as of 2026-10-25
Upcoming catalysts
buntanetap — Topline data
Q1 2027
The Company plans a database lock for the 6-month analysis in Q1 2027, with the top-line symptomatic data readout anticipated in the same quarter.Source filing
buntanetap — Topline data
Q1 2027
· Q1 2027: 6-month symptomatic top-line data readoutSource filing
buntanetap — NDA/BLA submission
early 2027
New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028Source filing
buntanetap — Clinical data readout
H2 2027
The 18-month disease modifying component is expected to read out in the second half of 2027.Source filing
buntanetap — Topline data
Q1 2028
· Q1 2028: 18-month disease-modifying top-line data readoutSource filing
buntanetap — NDA/BLA submission
early 2028
New Drug Application (NDA) for buntanetap as a symptomatic treatment for AD is expected in early 2027 and as a potential disease-modifying treatment in early 2028Source filing